Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (n = 23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an important treatment option in the heavily pretreated cHL patients.

古典霍奇金淋巴瘤（cHL）被认为是可以治愈的疾病；但是，在大约三分之一的反应患者中，该疾病在治疗完成后会复发。批准用于治疗复发性/难治性cHL的药物之一是nivolumab，它是一种免疫检查点抑制剂，可通过阻断程序性死亡1（PD-1）受体显示其作用。在这项研究中，我们提供了一项回顾性“现实生活”分析，该研究对已加入指定患者方案（NPP）的复发/难治性cHL患者中的复发/难治性cHL患者的使用进行了回顾，反映了4年治疗复发/难治性CHL。我们对24个不同中心参加NPP的87例患者（中位年龄为30岁）进行了回顾性分析，复发/难治性cHL并因此接受nivolumab治疗的患者。中位随访时间为29个月，先前治疗的中位数为5（2-11）。在这项研究中，最佳的总体缓解率为70％（CR为36％； PR为34％）。28名反应患者接受了随后的干细胞移植（SCT）。在接受异体干细胞移植的15例患者中，有9例进行了客观缓解的移植，其中8例目前还活着并且正在进行缓解。在分析时，有23名患者继续接受nivolumab治疗，其余患者停止治疗。停用nivolumab的主要原因是疾病进展（最佳总体缓解率为70％（CR为36％； PR为34％）。28名反应患者接受了随后的干细胞移植（SCT）。在接受异体干细胞移植的15例患者中，有9例进行了客观缓解的移植，其中8例目前还活着并且正在进行缓解。在分析时，有23名患者继续接受nivolumab治疗，其余患者停止治疗。停用nivolumab的主要原因是疾病进展（最佳总体缓解率为70％（CR为36％； PR为34％）。28名反应患者接受了随后的干细胞移植（SCT）。在接受异体干细胞移植的15例患者中，有9例进行了客观缓解的移植，其中8例目前还活着并且正在进行缓解。在分析时，仍有23例患者接受nivolumab治疗，其余患者停止治疗。停用nivolumab的主要原因是疾病进展（23例患者继续接受nivolumab治疗，其余患者停止治疗。停用nivolumab的主要原因是疾病进展（23例患者继续接受nivolumab治疗，其余患者停止治疗。停用nivolumab的主要原因是疾病进展（n = 23）。安全性是可以接受的，只有9名患者因严重不良事件而需要停用nivolumab。24个月无进展生存率和总生存率分别为58.5％（95％CI，0.47-0.68）和78.7％（95％CI，0.68-0.86）。随访期间有18例患者死亡，只有其中1例与治疗有关。凭借其功效和安全性，PD-1阻滞剂已成为经过大量预处理的cHL患者的重要治疗选择。